Nature Biotechnology published a piece arguing that hybrid quantum–classical computers could achieve “quantum advantage” in biotechnology before fully capable quantum machines are available. The report focuses on near-term architectures that combine classical processing with quantum components, positioning them as a bridge toward later, more capable quantum systems. For biotech, the practical question is whether these systems can accelerate specific tasks—such as simulation, optimization, or modeling—that benefit from quantum methods. As a development signal, the story highlights ongoing engineering and algorithm work that could expand the biotech computational toolkit even while the sector waits for broader quantum hardware maturity.